EVOLUTION IN MANAGEMENT OF STAGE I SEMINOMA: THE CASE FOR PATIENT PREFERENCE AND PATIENT/CLINICIAN JOINT INTERNET REGISTRATION AND FOLLOW-UP STUDY TO QUANTIFY LATE EVENTS.

The author reflects on the study by Vossen and colleagues which investigated the developments in stage I seminoma management. He congratulates the author for their comprehensive assessment of variation in the management throughout Eastern, Western, and Central Europe. He says that the authors were not able to cover the issue on the 78% reduction by one-day carboplatin treatment in contralateral germ cell testis tumours.